For example, miR-106a-3p/5p is recognized for targeting PTEN in prostate cancer, while the miR-125 cluster significantly influences the same type of cancer by targeting p53 inhibitors (Wu et al., 2024). This evidence concerns the gene TP53 and prostate carcinoma.